Regulatory14 Aug 2026, 08:22 pm
Orchid Pharma: QIP Proceeds Reallocation Approved by Shareholders
AI Summary
Orchid Pharma Ltd has filed a Statement of Deviation or Variation for the quarter ended June 30, 2026, regarding the use of proceeds from its Qualified Institutional Placement (QIP). The company raised ₹400 Crores on June 27, 2023. A deviation in fund utilization was noted and approved by shareholders on September 20, 2025. The modification in allocation is due to changes in the business environment and strategic requirements, leading to the postponement of the 'new block at API Facility' project. Proceeds originally allocated to this project have been reallocated to mitigate financial burdens and ensure optimal utilization. The Audit Committee has reviewed the statement.
Key Highlights
- Orchid Pharma reports deviation in QIP fund utilization for Q2 FY26.
- Shareholders approved reallocation of funds due to business environment changes.
- API Facility project commencement postponed, impacting fund allocation.
- Proceeds reallocated to improve profitability and ensure best utilization.
- Audit Committee has reviewed the deviation statement.
Price Impact
More from ORCHPHARMA